Hey Bull, hard to say. Generic Endocrine/nash/testosterone players or anyone looking to enter any of those spaces. You could make a decent list with that alone. Some tech is going to need validated first, by us or our competition, for a real deal, imho. Don’t think it makes sense to settle for phase 1 /2 type values if you are ligand, with so many irons in the fire. I don’t think anyone is yet willing to pay the premium it would take, esp with how derisked they are (ligand) to continue forward, available data considered. This may be bigger than I thought, if April/May treats us well. Have a good week, best of luck
News 
Market Data 
Discover 
